MetaCap

Pasithea Therapeutics Corp. (KTTA)

NASDAQ: KTTAHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.4787-0.0023 (-0.48%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

KTTA stock chart

Technical analysis

Key statistics

All statistics
Market cap
$17.59M
EPS (TTM)
-$1.38
52-week range
0.32 – 2.06
Day range
0.4701 – 0.515
Volume / Avg
100.72K / 705.64K
Beta
—

52-week range

$0.32$2.06

KTTA stock today

Pasithea Therapeutics (KTTA) closed at $0.4787 on Nov 20, down 0.48% (-$0.0023), versus the S&P 500's 3.70% decline. Trading was light, with 100.72K shares changing hands, about 14% of the average daily volume. At this level, KTTA sits near the bottom of its 52-week range of $0.32 to $2.06: 76.8% below the high, set on Nov 28, 2025 and 49.6% above the low.

KTTA is down 62.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 63.9%. Pasithea Therapeutics has posted a net loss over the last twelve months (EPS of -$1.38), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Pasithea Therapeutics

Company profile

Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Tiago Reis Marques M.D., Ph.D.
Headquarters
Miami Beach, FL
Employees
5
IPO year
2021

Financial highlights

Full financials

Pasithea Therapeutics reported a net loss of $20.4 million, compared with a loss of $13.9 million a year earlier. Diluted earnings per share came in at -$2.91.

Pasithea Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue———$486.56K$15.06K
Growth———+3130.37%—
Net income$-20.43M$-13.90M$-15.96M$-13.94M$-2.17M
EPS (diluted)$-2.91$-12.69$-0.42$-1.76$-0.21

Analyst forecast

Forecast

Consensus (1 analysts)

none

Avg. price target

$3.00+526.70%

  • Strong buy 0
  • Buy 1
  • Hold 0
  • Sell 0
  • Strong sell 0

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 13, 2026
EPS actual vs est.
$-0.20 vs $-0.21
Surprise
+4.76%

KTTA news

All KTTA news

Pasithea Therapeutics peers

Health Care sector
KTTA peer companies
CompanyPrice% ChgMarket capCompare
MRKRMarker Therapeutics Inc.1.09-17.42%$18.17Mvs KTTA
COCPCocrystal Pharma Inc.0.95-2.05%$18.30Mvs KTTA
AKTXAkari Therapeutics plc ADS7.18+7.00%$16.70Mvs KTTA
SHPHShuttle Pharmaceuticals Holdings Inc.3.49-10.51%$16.63Mvs KTTA
CPHIChina Pharma Holdings Inc.0.4384-13.00%$18.86Mvs KTTA
LPCNLipocine Inc.1.48-1.33%$16.39Mvs KTTA
ATOSAtossa Therapeutics Inc.1.60-8.86%$15.92Mvs KTTA
PBMPsyence Biomedical Ltd.2.97+3.85%$15.80Mvs KTTA

Indexes, lists and sector

Pasithea Therapeutics stock FAQ

What is Pasithea Therapeutics's stock price today?

KTTA last traded at $0.4787 as of Nov 20, 4:00 PM EST, down 0.48% on the day. Prices are delayed at least 15 minutes.

Does Pasithea Therapeutics pay a dividend?

No. Pasithea Therapeutics does not currently pay a regular cash dividend.

Who is Pasithea Therapeutics's CEO?

Dr. Tiago Reis Marques M.D., Ph.D. is the chief executive officer of Pasithea Therapeutics Corp., which has about 5 employees.

Has KTTA ever split its stock?

Yes. The most recent KTTA stock split was a 1-for-20 split on Jan 2, 2024.

What is the KTTA 52-week high?

The 52-week high for KTTA is $2.06 and the 52-week low is $0.32. The stock is currently 76.8% below its high.

Compare KTTA